A BILL 
To amend title XI of the Social Security Act to establish 
the American Insulin Program to provide for lower prices 
for insulin drugs, to maintain effort throughout the insu-
lin supply chain, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Affordable Insulin for 
4
All Act’’. 
5
03:14 Feb 05, 2020
H5749
2 
•HR 5749 IH
SEC. 2. PROVIDING FOR LOWER PRICES FOR INSULIN 
1
DRUGS. 
2
Part A of title XI of the Social Security Act (42 
3
U.S.C. 1301) is amended by adding at the end the fol-
4
lowing new section: 
5
‘‘SEC. 1150C. ESTABLISHMENT OF PROGRAM. 
6
‘‘(a) IN GENERAL.—The Secretary shall establish an 
7
American Insulin Program (in this section referred to as 
8
the ‘program’) by not later than 30 days after the date 
9
of the enactment of this section. Under the program, the 
10
Secretary shall enter into agreements described in sub-
11
section (b) with manufacturers and provide for the per-
12
formance of duties described in subsection (c). The Sec-
13
retary shall establish a model agreement for use under the 
14
program by not later than 20 days after the date of the 
15
enactment of this section, in consultation with manufac-
16
turers, and allow for comment on such model agreement. 
17
‘‘(b) TERMS OF AGREEMENT.— 
18
‘‘(1) IN GENERAL.— 
19
‘‘(A) AGREEMENT.—An agreement under 
20
this section shall require the manufacturer to 
21
provide applicable individuals access to Med-
22
icaid prices for insulin drugs of the manufac-
23
turer. 
24
‘‘(B) PROVISION OF DISCOUNTED PRICES 
25
AS THE POINT-OF-SALE.— 
26
03:14 Feb 05, 2020
H5749
3 
•HR 5749 IH
‘‘(i) IN GENERAL.—Subject to clause 
1
(ii), such Medicaid prices shall be provided 
2
to the applicable beneficiary at the phar-
3
macy or by the mail order service at the 
4
point-of-sale of an insulin drug. 
5
‘‘(ii) 
CERTIFICATION
OF 
6
UNSUSTAINABLE REVENUES.— 
7
‘‘(I) IN GENERAL.—In the case 
8
the Secretary submits to Congress a 
9
certification that net revenues from 
10
the sale of insulin drugs by manufac-
11
turers with an agreement under this 
12
section is unsustainable because such 
13
manufactures will be unable to meet 
14
the demand for insulin drugs in the 
15
United States, subject to subclause 
16
(II), the Secretary may increase the 
17
Medicaid price by 5 percent. 
18
‘‘(II) 
LIMITATION.—The 
Sec-
19
retary may not increase the Medicaid 
20
price in accordance with subclause (I) 
21
more than 3 times. 
22
‘‘(III) APPLICABILITY OF PRICE 
23
INCREASE.—An increase to the Med-
24
icaid price of insulin drugs described 
25
03:14 Feb 05, 2020
H5749
4 
•HR 5749 IH
in subclause (I) shall apply to the sale 
1
of insulin drugs 90 days after the 
2
date of a certification described in 
3
such subclause. 
4
‘‘(C) TIMING OF AGREEMENT.— 
5
‘‘(i) SPECIAL
RULE
FOR
2021.—In 
6
order for an agreement with a manufac-
7
turer to be in effect under this section with 
8
respect to the period beginning on January 
9
1, 2021, and ending on December 31, 
10
2021, the manufacturer shall enter into 
11
such agreement not later than 30 days 
12
after the date of the establishment of a 
13
model agreement under subsection (a). 
14
‘‘(ii) 
2022 
AND
SUBSEQUENT 
15
YEARS.—In order for an agreement with a 
16
manufacturer to be in effect under this 
17
section with respect to plan year 2022 or 
18
a subsequent plan year, the manufacturer 
19
shall enter into such agreement (or such 
20
agreement shall be renewed under para-
21
graph (4)(A)) not later than January 30 of 
22
the preceding year. 
23
‘‘(2) PROVISION OF APPROPRIATE DATA.—Each 
24
manufacturer with an agreement in effect under this 
25
03:14 Feb 05, 2020
H5749
5 
•HR 5749 IH
section shall collect and have available appropriate 
1
data, as determined by the Secretary, to ensure that 
2
it can demonstrate to the Secretary compliance with 
3
the requirements under the program. 
4
‘‘(3) COMPLIANCE
WITH
REQUIREMENTS
FOR 
5
ADMINISTRATION
OF
PROGRAM.—Each manufac-
6
turer with an agreement in effect under this section 
7
shall comply with requirements imposed by the Sec-
8
retary or a third party with a contract under sub-
9
section (d)(3), as applicable, for purposes of admin-
10
istering the program, including any determination 
11
under clause (i) of subsection (c)(1)(A) or proce-
12
dures established under such subsection (c)(1)(A). 
13
‘‘(4) LENGTH OF AGREEMENT.— 
14
‘‘(A) IN GENERAL.—An agreement under 
15
this section shall be effective for an initial pe-
16
riod of not less than 18 months and shall be 
17
automatically renewed for a period of not less 
18
than 1 year unless terminated under subpara-
19
graph (B). 
20
‘‘(B) TERMINATION.— 
21
‘‘(i) BY THE SECRETARY.—The Sec-
22
retary may provide for termination of an 
23
agreement under this section for a knowing 
24
and willful violation of the requirements of 
25
03:14 Feb 05, 2020
H5749
6 
•HR 5749 IH
the agreement or other good cause shown. 
1
Such termination shall not be effective ear-
2
lier than 30 days after the date of notice 
3
to the manufacturer of such termination. 
4
The Secretary shall provide, upon request, 
5
a manufacturer with a hearing concerning 
6
such a termination, and such hearing shall 
7
take place prior to the effective date of the 
8
termination with sufficient time for such 
9
effective date to be repealed if the Sec-
10
retary determines appropriate. 
11
‘‘(ii) BY A MANUFACTURER.—A man-
12
ufacturer may terminate an agreement 
13
under this section for any reason. Any 
14
such termination shall be effective, with re-
15
spect to a plan year— 
16
‘‘(I) if the termination occurs be-
17
fore January 30 of a plan year, as of 
18
the day after the end of the plan year; 
19
and 
20
‘‘(II) if the termination occurs on 
21
or after January 30 of a plan year, as 
22
of the day after the end of the suc-
23
ceeding plan year. 
24
03:14 Feb 05, 2020
H5749
7 
•HR 5749 IH
‘‘(iii) EFFECTIVENESS
OF
TERMI-
1
NATION.—Any termination under this sub-
2
paragraph shall not affect discounts for in-
3
sulin drugs of the manufacturer that are 
4
due under the agreement before the effec-
5
tive date of its termination. 
6
‘‘(iv) NOTICE TO THIRD PARTY.—The 
7
Secretary shall provide notice of such ter-
8
mination to a third party with a contract 
9
under subsection (d)(3) within not less 
10
than 30 days before the effective date of 
11
such termination. 
12
‘‘(c) DUTIES DESCRIBED.—The duties described in 
13
this subsection are the following: 
14
‘‘(1) ADMINISTRATION OF PROGRAM.—Admin-
15
istering the program, including— 
16
‘‘(A) the determination of the amount of 
17
the Medicaid price of an insulin drug of a man-
18
ufacturer for applicable individuals in each 
19
State; 
20
‘‘(B) except as provided in subparagraph 
21
(C), the establishment of procedures under 
22
which Medicaid prices are provided to applica-
23
ble individuals at pharmacies or by mail order 
24
service at the point-of-sale of an insulin drug; 
25
03:14 Feb 05, 2020
H5749
8 
•HR 5749 IH
‘‘(C) in the case where, during the period 
1
beginning on January 1, 2022, and ending on 
2
December 31, 2022, it is not practicable to pro-
3
vide such Medicaid prices at the point-of-sale 
4
(as described in subparagraph (B)), the estab-
5
lishment of procedures to provide such Medicaid 
6
prices as soon as practicable after the point-of- 
7
sale; 
8
‘‘(D) the establishment of procedures to 
9
ensure that, not later than the applicable num-
10
ber of calendar days after the dispensing of an 
11
insulin drug by a pharmacy or mail order serv-
12
ice, the pharmacy or mail order service is reim-
13
bursed for an amount equal to the difference 
14
between— 
15
‘‘(i) the negotiated price of the insulin 
16
drug; and 
17
‘‘(ii) the Medicaid price of the insulin 
18
drug; and 
19
‘‘(E) providing a reasonable dispute resolu-
20
tion mechanism to resolve disagreements be-
21
tween manufacturers, applicable individuals, 
22
and the third party with a contract under sub-
23
section (d)(3). 
24
‘‘(2) MONITORING COMPLIANCE.— 
25
03:14 Feb 05, 2020
H5749
9 
•HR 5749 IH
‘‘(A) IN
GENERAL.—The Secretary shall 
1
monitor compliance by a manufacturer with the 
2
terms of an agreement under this section. 
3
‘‘(B) NOTIFICATION.—If a third party 
4
with a contract under subsection (d)(3) deter-
5
mines that the manufacturer is not in compli-
6
ance with such agreement, the third party shall 
7
notify the Secretary of such noncompliance for 
8
appropriate enforcement under subsection (e). 
9
‘‘(3) COLLECTION OF DATA FROM STATE MED-
10
ICAID PROGRAMS.—The Secretary may collect appro-
11
priate data from each State Medicaid program under 
12
title XIX in a timeframe that allows for Medicaid 
13
prices to be provided for applicable drugs under this 
14
section. 
15
‘‘(d) ADMINISTRATION.— 
16
‘‘(1) IN GENERAL.—Subject to paragraph (2), 
17
the Secretary shall provide for the implementation of 
18
this section, including the performance of the duties 
19
described in subsection (c). 
20
‘‘(2) LIMITATION.— 
21
‘‘(A) IN
GENERAL.—Subject to subpara-
22
graph (B), in providing for such implementa-
23
tion, the Secretary shall not receive or dis-
24
03:14 Feb 05, 2020
H5749
10 
•HR 5749 IH
tribute any funds of a manufacturer under the 
1
program. 
2
‘‘(B) EXCEPTION.—The limitation under 
3
subparagraph (A) shall not apply to the Sec-
4
retary with respect to insulin drugs dispensed 
5
during the period beginning on January 1, 
6
2022, and ending on December 31, 2022, but 
7
only if the Secretary determines that the excep-
8
tion to such limitation under this subparagraph 
9
is necessary in order for the Secretary to begin 
10
implementation of this section and provide ap-
11
plicable beneficiaries timely access to Medicaid 
12
prices during such period. 
13
‘‘(3) CONTRACT
WITH
THIRD
PARTIES.—The 
14
Secretary shall enter into a contract with 1 or more 
15
third parties to administer the requirements estab-
16
lished by the Secretary in order to carry out this 
17
section. At a minimum, the contract with a third 
18
party under the preceding sentence shall require 
19
that the third party— 
20
‘‘(A) receive and transmit information be-
21
tween the Secretary, manufacturers, and other 
22
individuals or entities the Secretary determines 
23
appropriate; 
24
03:14 Feb 05, 2020
H5749
11 
•HR 5749 IH
‘‘(B) receive, distribute, or facilitate the 
1
distribution of funds of manufacturers to ap-
2
propriate individuals or entities in order to 
3
meet the obligations of manufacturers under 
4
agreements under this section; 
5
‘‘(C) provide adequate and timely informa-
6
tion to manufacturers, consistent with the 
7
agreement with the manufacturer under this 
8
section, as necessary for the manufacturer to 
9
fulfill its obligations under this section; and 
10
‘‘(D) permit manufacturers to conduct 
11
periodic audits, directly or through contracts, of 
12
the data and information used by the third 
13
party to determine discounts for insulin drugs 
14
of the manufacturer under the program. 
15
‘‘(4) 
PERFORMANCE
REQUIREMENTS.—The 
16
Secretary shall establish performance requirements 
17
for a third party with a contract under paragraph 
18
(3) and safeguards to protect the independence and 
19
integrity of the activities carried out by the third 
20
party under the program under this section. 
21
‘‘(5) IMPLEMENTATION.—The Secretary may 
22
implement the program under this section by pro-
23
gram instruction or otherwise. 
24
03:14 Feb 05, 2020
H5749
12 
•HR 5749 IH
‘‘(6) ADMINISTRATION.—Chapter 35 of title 44, 
1
United States Code, shall not apply to the program 
2
under this section. 
3
‘‘(e) ENFORCEMENT.— 
4
‘‘(1) AUDITS.—Each manufacturer with an 
5
agreement in effect under this section shall be sub-
6
ject to periodic audit by the Secretary. 
7
‘‘(2) CIVIL MONETARY PENALTY.— 
8
‘‘(A) IN
GENERAL.—The Secretary shall 
9
impose a civil money penalty on a manufacturer 
10
that fails to provide individuals Medicaid prices 
11
for insulin drugs of the manufacturer in accord-
12
ance with such agreement for each such failure 
13
in an amount the Secretary determines is com-
14
mensurate with the sum of— 
15
‘‘(i) the amount that the manufac-
16
turer would have paid with respect to such 
17
discounts under the agreement, which will 
18
then be used to pay the discounts which 
19
the manufacturer had failed to provide; 
20
and 
21
‘‘(ii) 25 percent of such amount. 
22
‘‘(B) APPLICATION.—The provisions of 
23
section 1128A (other than subsections (a) and 
24
(b)) shall apply to a civil money penalty under 
25
03:14 Feb 05, 2020
H5749
13 
•HR 5749 IH
this paragraph in the same manner as such 
1
provisions apply to a penalty or proceeding 
2
under section 1128A(a). 
3
‘‘(f) DEFINITIONS.—In this section: 
4
‘‘(1) APPLICABLE INDIVIDUAL.—The term ‘ap-
5
plicable individual’ means an individual who has re-
6
ceived a diagnosis of diabetes. 
7
‘‘(2) APPLICABLE
NUMBER
OF
CALENDAR 
8
DAYS.—The term ‘applicable number of calendar 
9
days’ means— 
10
‘‘(A) with respect to claims for reimburse-
11
ment submitted electronically, 14 days; and 
12
‘‘(B) with respect to claims for reimburse-
13
ment submitted otherwise, 30 days. 
14
‘‘(3) INSULIN DRUG.—The term ‘insulin drug’ 
15
means a medication approved by the Food and Drug 
16
Administration to treat high blood glucose. 
17
‘‘(4) MANUFACTURER.—The term ‘manufac-
18
turer’ means, with respect to insulin drugs, any enti-
19
ty which is engaged in the production, preparation, 
20
propagation, compounding, conversion, or processing 
21
of prescription drug products, either directly or indi-
22
rectly by extraction from substances of natural ori-
23
gin, or independently by means of chemical syn-
24
thesis, or by a combination of extraction and chem-
25
03:14 Feb 05, 2020
H5749
14 
•HR 5749 IH
ical synthesis. Such term does not include a whole-
1
sale distributor of insulin drugs or a retail pharmacy 
2
licensed under State law. 
3
‘‘(5) MEDICAID PRICE.— 
4
‘‘(A) IN
GENERAL.—The term ‘Medicaid 
5
price’ means, with respect to an individual enti-
6
tled to medical assistance under title XIX, the 
7
net receipt specified in subparagraph (B) for 
8
the dosage form and strength of an insulin drug 
9
and any increase due to a certification de-
10
scribed in subsection (b)(1)(B)(ii)(I). 
11
‘‘(B) NET RECEIPT SPECIFIED.—For pur-
12
poses of subparagraph (A), the net receipt spec-
13
ified in this subparagraph shall be equal to the 
14
product of— 
15
‘‘(i) the total number of units of each 
16
dosage form and strength purchased under 
17
the program in the rebate period (as deter-
18
mined by the Secretary), and 
19
‘‘(ii) the amount that is the list price 
20
of such drug during such rebate period, 
21
less, the total amount of rebates that the manu-
22
facturer paid with respect to such drug during 
23
such rebate period. 
24
03:14 Feb 05, 2020
H5749
15 
•HR 5749 IH
‘‘(6) NEGOTIATED
PRICE.—The term ‘nego-
1
tiated price’ has the meaning given such term in sec-
2
tion 423.100 of title 42, Code of Federal Regula-
3
tions (as in effect on the date of enactment of this 
4
section), except that such negotiated price shall not 
5
include any dispensing fee for the applicable drug.’’. 
6
SEC. 3. MAINTENANCE OF EFFORT THROUGHOUT THE IN-
7
SULIN SUPPLY CHAIN. 
8
(a) ELIMINATION
OF
PBM REBATES.—Section 
9
1128B(b)(3) of the Social Security Act (42 U.S.C. 1320a– 
10
7b(b)(3)) is amended— 
11
(1) in subparagraph (E), by inserting ‘‘(except 
12
for a payment practice that permits rebates, dis-
13
counts, or price concessions for insulin drugs (as de-
14
fined in section 1150C(f)(3)) to be paid by a manu-
15
facturer to a PBM (as defined in section 1150A(a))’’ 
16
before the semicolon at the end; and 
17
(2) in subparagraph (J)— 
18
(A) by moving the margin two ems to the 
19
left; and 
20
(B) by inserting ‘‘(except for an insulin 
21
drug)’’ after ‘‘section 1860D–14A(g)’’. 
22
(b) EXCLUSION
OF
INSULIN
PAYMENTS
FROM 
23
MLR.—Not later than 90 days after the date of the enact-
24
ment of this Act, the Secretary of Health and Human 
25
03:14 Feb 05, 2020
H5749
16 
•HR 5749 IH
Services shall exclude, beginning with plan years begin-
1
ning on or after January 1, 2021, from the denominator 
2
(as defined in section 158.221(c) of title 45, Code of Fed-
3
eral Regulations) section of a medical loss ratio (as cal-
4
culated under section 158.221(a) of such title) of a health 
5
insurance issuer (as defined in section 144.103 of such 
6
title) the amount of payments that such issuer paid during 
7
a MLR reporting year (as defined in section 144.103 of 
8
such title) for insulin drugs through the promulgation of 
9
a regulation. 
10
(c) MAXIMUM COST SHARING
AND COINSURANCE 
11
FOR INSULIN DRUGS IN CERTAIN PRIVATE PLANS AND 
12
MEDICARE.— 
13
(1) PHSA AMENDMENT.—Subpart II of part A 
14
of title XXVII of the Public Health Service Act (42 
15
U.S.C. 300gg–11 et seq.) is amended by inserting 
16
after section 2713 the following new section: 
17
‘‘SEC. 2713A. COVERAGE OF INSULIN DRUGS. 
18
‘‘(a) IN GENERAL.—Beginning with plan years begin-
19
ning 90 days after the date of the enactment of this sec-
20
tion, a group health plan and a health insurance issuer 
21
offering group or individual health insurance coverage 
22
shall, at a minimum provide coverage and may impose cost 
23
sharing for an insulin drug in accordance with subsection 
24
03:14 Feb 05, 2020
H5749
17 
•HR 5749 IH
(b) for an individual that is provided a prescription for 
1
such drug. 
2
‘‘(b) COST SHARING.—Beginning with plan years be-
3
ginning 90 days after the date of the enactment of this 
4
section, the cost sharing incurred under a plan or coverage 
5
described in subsection (a) for an insulin drug may not 
6
exceed $10 for each 1-month period of coverage. 
7
‘‘(c) INSULIN DRUG DEFINED.—In this section, the 
8
term ‘insulin drug’ has the meaning given such term in 
9
section 1150C(f)(3) of the Social Security Act.’’. 
10
(2) MEDICARE AMENDMENTS.— 
11
(A) COINSURANCE
LIMITATION.—Section 
12
1860D–2(b)(2) of the Social Security Act (42 
13
U.S.C. 1395w–102(b)(2)) is amended— 
14
(i) in subparagraph (A), by striking 
15
‘‘Subject to subparagraphs (C) and (D)’’ 
16
and inserting ‘‘Subject to subparagraphs 
17
(C), (D), and (E)’’; and 
18
(ii) by adding at the end, the fol-
19
lowing new subparagraph: 
20
‘‘(E) COVERAGE
FOR
INSULIN
DRUGS.— 
21
Beginning with plan years beginning 90 days 
22
after the date of the enactment of this subpara-
23
graph, the coverage has coinsurance (for costs 
24
above the annual deductible specified in para-
25
03:14 Feb 05, 2020
H5749
18 
•HR 5749 IH
graph (1) and up to the initial coverage limit 
1
under paragraph (3)) for an insulin drug (as 
2
defined in section 1861(kkk)) is not more than 
3
$10 for each 1-month period of coverage.’’. 
4
(B) INSULIN
DRUG
DEFINED.—Section 
5
1861 of the Social Security Act (42 U.S.C. 
6
1395x) is amended by adding at the end the 
7
following new subsection: 
8
‘‘(kkk) INSULIN DRUG.—The term ‘insulin drug’ has 
9
the meaning given such term in section 1150C(f)(3) fur-
10
nished on or after 90 days after the date of the enactment 
11
of this subsection.’’. 
12
(d) FREEZING
OF SUPPLEMENTAL REBATES
IN 
13
MEDICAID.—Section 1902(a) of the Social Security Act 
14
(42 U.S.C. 1396a(a)) is amended— 
15
(1) in paragraph (85), by striking at the end 
16
‘‘and’’; 
17
(2) in paragraph (86), by striking the period at 
18
the end and inserting ‘‘; and’’; and 
19
(3) by inserting after paragraph (86), the fol-
20
lowing new paragraph: 
21
‘‘(87) provide that the State may not— 
22
‘‘(A) secure from the manufacturer of a 
23
drug payable under this title a supplemental re-
24
bate that is not a rebate under section 1927 
25
03:14 Feb 05, 2020
H5749
19 
•HR 5749 IH
that exceeds the amount of the supplemental re-
1
bate on the date of the enactment of this para-
2
graph; or 
3
‘‘(B) secure any other supplemental re-
4
bates.’’. 
5
(e) ELIMINATION
OF SPREAD PRICING
AND RE-
6
LATED PRACTICES IN MEDICAID.— 
7
(1) IN GENERAL.—Section 1927(e) of the So-
8
cial Security Act (42 U.S.C. 1396r–8(e)) is amended 
9
by adding at the end the following: 
10
‘‘(6) PASS-THROUGH
PRICING
REQUIRED.—A 
11
contract between the State and a pharmacy benefit 
12
manager (referred to in this paragraph as a ‘PBM’), 
13
or a contract between the State and a managed care 
14
entity or other specified entity (as such terms are 
15
defined in section 1903(m)(9)(D)) that includes pro-
16
visions making the entity responsible for coverage of 
17
covered outpatient drugs dispensed to individuals en-
18
rolled with the entity, shall require that payment for 
19
such drugs and related administrative services (as 
20
applicable), including payments made by a PBM on 
21
behalf of the State or entity, is based on a pass- 
22
through pricing model under which— 
23
‘‘(A) any payment made by the entity or 
24
the PBM (as applicable) for such a drug— 
25
03:14 Feb 05, 2020
H5749
20 
•HR 5749 IH
‘‘(i) is limited to— 
1
‘‘(I) ingredient cost; and 
2
‘‘(II) a professional dispensing 
3
fee that is not less than the profes-
4
sional dispensing fee that the State 
5
plan or waiver would pay if the plan 
6
or waiver was making the payment di-
7
rectly; 
8
‘‘(ii) is passed through in its entirety 
9
by the entity or PBM to the pharmacy 
10
that dispenses the drug; and 
11
‘‘(iii) is made in a manner that is con-
12
sistent with section 1902(a)(30)(A) and 
13
sections 447.512, 447.514, and 447.518 of 
14
title 42, Code of Federal Regulations (or 
15
any successor regulation) as if such re-
16
quirements applied directly to the entity or 
17
the PBM; 
18
‘‘(B) payment to the entity or the PBM 
19
(as applicable) for administrative services per-
20
formed by the entity or PBM is limited to a 
21
reasonable administrative fee that covers the 
22
reasonable cost of providing such services; 
23
‘‘(C) the entity or the PBM (as applicable) 
24
shall make available to the State, and the Sec-
25
03:14 Feb 05, 2020
H5749
21 
•HR 5749 IH
retary upon request, all costs and payments re-
1
lated to covered outpatient drugs and accom-
2
panying administrative services incurred, re-
3
ceived, or made by the entity or the PBM, in-
4
cluding ingredient costs, professional dispensing 
5
fees, administrative fees, post-sale and post-in- 
6
voice fees. Discounts, or related adjustments 
7
such as direct and indirect remuneration fees, 
8
and any and all remuneration; and 
9
‘‘(D) any form of spread pricing whereby 
10
any amount charged or claimed by the entity or 
11
the PBM (as applicable) that is in excess of the 
12
amount paid to the pharmacies on behalf of the 
13
entity, including any post-sale or post-invoice 
14
fees, discounts, or related adjustments such as 
15
direct and indirect remuneration fees or assess-
16
ments (after allowing for a reasonable adminis-
17
trative fee as described in subparagraph (B)), is 
18
not allowable for purposes of claiming Federal 
19
matching payments under this title.’’. 
20
(2) CONFORMING
AMENDMENT.—Clause (xiii) 
21
of section 1903(m)(2)(A) of such Act (42 U.S.C. 
22
1396b(m)(2)(A)) is amended— 
23
(A) by striking ‘‘and (III)’’ and inserting 
24
‘‘(III)’’; and 
25
03:14 Feb 05, 2020
H5749
22 
•HR 5749 IH
(B) by inserting before the period at the 
1
end the following: ‘‘, and (IV) pharmacy benefit 
2
management services provided by the entity, or 
3
provided by a pharmacy benefit manager on be-
4
half of the entity under a contract or other ar-
5
rangement between the entity and the phar-
6
macy benefit manager, shall comply with the re-
7
quirements of section 1927(e)(6)’’. 
8
(3) EFFECTIVE DATE.—The amendments made 
9
by this subsection apply to contracts between States 
10
and managed care entities, other specified entities, 
11
or pharmacy benefits managers that are entered into 
12
or renewed on or after the date that is 90 days after 
13
the date of enactment of this Act. 
14
SEC. 4. GAO REPORT. 
15
Not later than 180 days after the date of the enact-
16
ment of this Act, the Comptroller General of the United 
17
States shall submit to Congress a report on the feasibility 
18
and affordability of direct manufacturing by the Federal 
19
Government. 
20
Æ 
03:14 Feb 05, 2020
H5749
